Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices

NCT01897051 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT01897051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01897051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices
Lead sponsor
Yonsei University
Phase
Phase 2/3
Overall status
Unknown status
Start date
July 31, 2013
Completion date
June 30, 2017
Enrollment
140 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

liver cirrhosis, portal hypertension